Postpartum Depression Market Outlook 2024: Exclusive Report By The Business Research Company | Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Postpartum Depression Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The postpartum depression market size has grown exponentially in recent years. It will grow from $9.17 billion in 2023 to $12.15 billion in 2024 at a compound annual growth rate (CAGR) of 32.5%. The growth in the historic period can be attributed to maternal mental health awareness, research advancements, public health initiatives, increased screenings.

The postpartum depression market size is expected to see exponential growth in the next few years. It will grow to $36.96 billion in 2028 at a compound annual growth rate (CAGR) of 32.1%. The growth in the forecast period can be attributed to telehealth services, pharmacological advancements, maternal mental health legislation, mental health workforce expansion. Major trends in the forecast period include integrated care models, peer support programs, perinatal mental health apps, mental health screening tools.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13024&type=smp

Market Segmentation:
The main types of postpartum depression are postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder, postpartum panic disorder, postpartum post-traumatic stress disorder, postpartum psychosis and others. Postpartum blues is a frequent yet self-limiting disease that occurs shortly after childbirth and can manifest as a variety of symptoms, including mood swings, irritability and tearfulness. They are treated through various treatments such as psychotherapy, medication, supplements and others. They are administered in various ways, such as oral, parenteral and others. They are available in various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies and others. They are utilized by various end-users, such as hospitals, specialty clinics, home-care settings and others.

Major Driver - Rising Postpartum Depression Cases Fueling Growth In The Postpartum Depression Market
An increase in postpartum depression cases is expected to propel the growth of the postpartum depression market going forward. Postpartum depression is an exaggerated worry that develops after giving birth. There may be physical symptoms in addition to it. Postnatal depression and postpartum anxiety frequently coexist and in the first year after giving birth, symptoms might start at any time. Postpartum depression is frequently treated with psychotherapy, commonly known as talk therapy or mental health counseling, medication, or a combination of the two, which results in the growth of the market. For Instance, in May 2022, according to UVA Medical Center, a US-based academic medical center with hospitals and specialty clinics, in the US the rates of postpartum depression symptoms steadily increased by 7.7% between December 2020 and March 2021. Further, there was an increase in postpartum depression symptoms in 36 of the 50 U.S. states and the District of Columbia in 2021. Therefore, an increase in postpartum depression cases will drive the postpartum depression market.

Competitive Landscape:
Major players in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report

Top Trend - Companies Innovating In The Postpartum Depression Market With Faster-Acting Therapies And Creative Care Delivery
Companies operating in the postpartum depression market are working on new product innovations to sustain their position in the market. The limited treatment choices have led to an increasing innovation need for faster-acting therapies and creative care delivery for postpartum depression. For instance, in February 2023, Biogen Inc., a US-based biotechnology company and Sage Therapeutics Inc., a US-based biopharmaceutical company, announced that the United States Food and Drug Administration (FDA) has accepted the filing of an NDA (new drug application) for zuranolone in the management of the major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an experimental medication that is being tested as a 14-day, once-daily, rapid-acting oral therapy in people with MDD and PPD. Zuranolone, a neuroactive steroid, acts as a positive allosteric modulator of GABA-A receptors, which is a unique method of action. It is supposed to operate in persons with depression by swiftly resetting dysregulated neural networks to help restore brain function. Zuranolone affects brain networks that control mood, arousal, behavior and even cognition.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Postpartum Depression Market Characteristics
3. Postpartum Depression Market Trends And Strategies
4. Postpartum Depression Market - Macro Economic Scenario
5. Postpartum Depression Market Size And Growth
…..
27. Postpartum Depression Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.